双虎清肝颗粒联合恩替卡韦片治疗HBeAg阳性慢性乙型肝炎48周疗效观察

目的 观察双虎清肝颗粒联合恩替卡韦片治疗HBeAg阳性慢性乙型肝炎(chronic hepatitis B,CHB)的临床疗效。方法 将120例HBeAg阳性CHB患者随机分为治疗组和对照组,每组60例。治疗组给予双虎清肝颗粒联合恩替卡韦片治疗,对照组给予恩替卡韦片治疗,治疗48周后比较2组ALT复常率、HBeAg转阴/血清学转换率、HBVDNA水平的变化及主要症状体征的改善情况。结果 治疗组ALT复常率、HBeAg转阴/血清学转换率及主要症状体征改善情况均显著优于对照组。结论 双虎清肝颗粒联合恩替卡韦片治疗HBeAg阳性CHB患者,在恢复肝功能、加快HBeAg转阴/血清学转换及改善患者临床症状等方面有较满意的疗效。

A 48-week antiviral efficacy of combination therapy of Shuanghu Qinggan Keli and entecavir tablets on HBeAg-positive patients with chronic hepatitis B

Objective To investigate the effect of combination therapy of Shuanghu Qinggan Keli and entecavir tablets on HBeAg-positive patients with chronic hepatitis B (CHB). Methods Totally 120 HBeAg-positive CHB patients were randomized into a treatment group and a control group, with 60 patients in each group. The treatment group was given entecavir tablets and Shuanghu Qinggan Keli, and the control group was administered with entecavir tablets. After 48 weeks of treatment, ALT normalization rates, HBeAg negative and seroconversion rates, HBV DNA levels and improvement of main signs and symptoms of the two groups were compared. Results ALT normalization rates, HBeAg negative and seroconversion rates and improvement of main signs and symptoms in the treatment group were superior to those in the control group. Conclusions Combination therapy of Shuanghu Qinggan Keli and entecavir tablets achieves good effects in recovering liver function, promoting HBeAg negative conversion and se-roconversion, and improving main signs and symptoms in HBeAg-positive CHB patients.